Recombinant α-mannosidase

Velmanase alfa

Brand names: Lamzede

Velmanase alfa is a recombinant human alpha-mannosidase enzyme replacement therapy for the non-neurological manifestations of alpha-mannosidosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It replaces deficient alpha-mannosidase, enabling lysosomal breakdown of accumulated mannose-rich oligosaccharides.

Prescribing in practice

Hypersensitivity and infusion-associated reactions, including anaphylaxis, can occur; administer under supervision with resuscitation facilities available.
It does not cross the blood–brain barrier and is not expected to affect the central neurological features of the disease.
It is given by intravenous infusion at regular intervals; refer to the SPC for administration guidance.

Monitoring

Patients are monitored during and after infusions for hypersensitivity, with periodic assessment of disease-related outcomes and antibody status as indicated.

Counselling the patient

This treatment is given as a regular drip and is a long-term therapy.
Report any rash, breathing difficulty, flushing or feeling unwell during or after an infusion.
Attend scheduled appointments so your response can be monitored.

Evidence & guidelines

Approval was based on clinical trials in alpha-mannosidosis evaluating functional and biochemical outcomes.

Reference: NICE HST15; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways